Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
Dr. Lena Al-Harthi speaks to News-Medical about her research into HIV treatment and the role of brain cells in spreading the HIV virus.
The antiretroviral drugs dolutegravir and emtricitabine/tenofovir alafenamide fumarate (DTG+FTC/TAF) may comprise the safest and most effective HIV treatment regimen currently available during pregnancy, researchers announced today.
Children born to women on HIV therapy containing the drug efavirenz were 2 to 2.5 times more likely to have microcephaly, or small head size, compared to children born to women on regimens of other antiretroviral drugs, according to an analysis funded by the National Institutes of Health.
As a raft of new treatments for HIV infection have come on the market in the past 20 years, AIDS patients got access to drugs that allowed them to live longer.
The accumulation of amyloid beta plaques and tangles of a protein called tau in the brain are hallmarks of Alzheimer's disease.
The National Institutes of Health has launched a large international study to compare the safety and efficacy of three antiretroviral treatment regimens for pregnant women living with HIV and the safety of these regimens for their infants.
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.
An enzyme that helps break down cholesterol may also be a therapeutic target to stave off neurologic diseases, including Alzheimer's and a rare genetic disorder, according to a new study published in the Journal of Biological Chemistry.
Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections in Seattle, a leading annual conference of HIV research, clinical practice and progress.
The drug combination emtricitabine/tenofovir alafenamide is approved in combination with other antiviral agents for the treatment of adults and adolescents infected with human immunodeficiency virus type 1 (HIV-1).
For a promising pathway to treating Alzheimer's patients, "aim here." That's what National Institute of Standards of Technology researchers advised collaborators hunting for molecules that, by linking to a normally occurring enzyme, rev up the brain's capacity for clearing cholesterol--a boost associated with improvements in memory and other benefits in animal studies.
A team led by researchers from UCSF and Yale has found that half of people newly infected with HIV experience neurologic issues. These neurologic findings are generally not severe and usually resolve after participants started anti-retroviral therapy.
A study led by Louise Kuhn, PhD, professor of Epidemiology at Columbia University's Mailman School of Public Health, evaluated whether HIV-infected children in South Africa who had achieved viral suppression with one antiretroviral treatment could transition to efavirenz-based therapy, the recommended drug for children older than 3 years, without risk of viral failure.
Nurse-trainer Helena Cumbelembe Inacio was struggling to teach nurses at the health center here the correct combination of medicines to prevent pregnant women with HIV from passing the infection to their children.
The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.
Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.
ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.
Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK.
Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.